PERTH – November 12, 2026 -- OncoRes Medical has rebranded as Ziva Surgical, moving its ELORA System, which holds FDA Breakthrough Device Designation and more than 44 granted patents, closer to commercialization.
Ziva Surgical targets residual cancer found after breast-conserving surgery
The Perth-based tissue intelligence company is addressing a persistent clinical gap: about one in five women undergoing breast-conserving surgery faces a second operation to remove residual cancer. Surgeons currently rely on sight, touch, specimen imaging and clinical judgment, methods that can leave residual cancer undetected during the procedure.
ELORA System converts surgeon's touch into microscale tissue maps
ELORA runs on quantitative micro-elastography (QME). It is designed to produce quantitative maps of tissue stiffness and microarchitecture inside the surgical cavity, so surgeons can decide what to remove and what to preserve. The company states the system is designed to complement pathology, not replace it.
QME was developed over more than a decade at the University of Western Australia and the Harry Perkins Institute of Medical Research. The company holds an exclusive commercial license, and its patent portfolio spans 10 patent families in key global markets.
Clinical results from Australian trial are due soon
The company is advancing its clinical development program ahead of commercialization. CEO Dr. Katharine Giles said the company is approaching some of its most significant clinical milestones, with results from its Australian clinical trial expected soon. The source gives no trial size, endpoints or launch timeline.
Prostate cancer is the next target after breast surgery
The company is initially focused on breast-conserving surgery, but plans to extend to other solid tumor cancers. Early feasibility studies in prostate cancer have shown promising results, according to the company. ELORA remains an investigational system.